Table 2.
Allelic variants by patient characteristics
| Combined H63D/C282Y (n=167) | H63D (n=172) | C282Y (n=179) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|||||||||
| Characteristics | Carrier (n=54) | Non-Carrier (n=113) | p value | Carrier (n=41) | Non-carrier (n=131) | p value | Carrier (n=18) | Non-carrier (n=161) | p value |
| Age at Diagnosis, years median (range) | 6.8 (<1–17.9) | 6.1 (<1–17.1) | 0.51 | 9.8 (1.5–17.6) | 6.1 (<1–17.9) | 0.22 | 3.9 (<1–17.6) | 7.0 (<1–17.6) | 0.44 |
| Age at Enrollment, years median (range) | 15.2 (4.6–31.4) | 15.2 (3.1–27.2) | 0.50 | 15.8 (6.4–31.4) | 15.2 (3.1–29.2) | 0.27 | 14.3 (4.6–29.2) | 15.3 (3.1–31.4) | 0.61 |
| Sex, Male, n (%) | 33 (61) | 58 (51) | 0.25 | 23 (56) | 71 (54) | 0.86 | 13 (72) | 85 (53) | 0.14 |
| Treatment, n (%) | |||||||||
| Doxorubicin only | 20 (37) | 41 (36) | 0.99 | 14 (34) | 49 (37) | 0.85 | 9 (50) | 57 (35) | 0.30 |
| Dexrazoxane Before Doxorubicin | 34 (63) | 72 (64) | 27 (66) | 92 (63) | 9 (50) | 104 (65) | |||
| Cumulative Doxorubicin Dose (mg/m2), median (range) | 300 (204–382) | 300 (240–366) | 0.54 | 300 (204–382) | 300 (240–420) | 0.79 | 300 (288–360) | 300 (204–382) | 0.82 |
|
| |||||||||
| Number of Patients Evaluable | 38 | 83 | 29 | 95 | 13 | 114 | |||
| Multiple Abnormal cTnT Measurements During Doxorubicin Treatment | 4 (11) | 7 (8) | 0.74 | 1 (3) | 10 (11) | 0.46 | 4 (31) | 7 (6) | 0.015 |
| Other* | 34 (89) | 76 (92) | 28 (97) | 85 (89) | 9 (69) | 107 (94) | |||
| Number of Patients Evaluable | 38 | 82 | 29 | 94 | 13 | 113 | |||
| Multiple Abnormal NT-proBNP Measurements During Doxorubicin Treatment | 33 (87) | 72 (88) | 0.99 | 25 (86) | 82 (87) | 0.99 | 11 (85) | 100 (88) | 0.65 |
| Other* | 5 (13) | 10 (12) | 4 (14) | 12 (13) | 2 (15) | 13 (12) | |||
*
Other: patients with no abnormal cTnT/NT-proBNP biomarker measurements or < 2 abnormal measurements